Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANX005 in Guillain-Barré Syndrome
NCT04701164Phase 3Completed
- Sponsor
- Annexon Biosciences
- Start
- Dec 2020
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of tanruprubart in Guillain-Barré syndrome (GBS), sponsored by Annexon Biosciences. Started Dec 2020; status: completed.
02
Drugs
tanruprubart
03
Conditions
Guillain-Barré syndrome (GBS)
Beyond the preview
Go deeper on NCT04701164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04701164.